Atara Biotherapeutics AI Price Prediction

The low PE ratio of 3.00 combined with a positive EPS of 3.15 suggests the market is heavily discounting Atara Biotherapeutics’ earnings, which is common for small-cap or turnaround biotech names. Without full revenue and margin history, the data implies recent profitability but with significant perceived risk or skepticism about its durability. Overall, valuation looks optically cheap, but the market appears unconvinced about long-term earnings visibility.

• PE ratio of 3.00 with positive EPS of 3.15 indicates the stock trades at a steep discount to current earnings, often signaling either deep value or high risk/low confidence in earnings sustainability.
• Positive EPS suggests the company is currently profitable on a per-share basis, which is notable for a biotech, but the market’s low multiple implies concerns about future cash flows, pipeline risk, or one-time/less-repeatable earnings drivers.
• In the absence of detailed revenue and margin trends, the combination of low multiple and positive earnings points to a potentially mispriced or highly speculative situation rather than a clearly strong or clearly weak fundamental profile.

Alternative data for Atara Biotherapeutics is mixed to muted. The company has 0 job openings with 0.0% month-over-month change, which suggests no active expansion signal from hiring but also no visible contraction from this data point alone. Social media presence is modest on Twitter/X and more substantial on LinkedIn, but follower growth appears flat on Twitter/X, implying limited recent momentum in online engagement.

• Zero current job openings and 0.0% month-over-month change indicate no clear hiring-driven growth signal; this can reflect either a stable, lean structure or a lack of active expansion initiatives.
• Twitter/X followers stand at 2,037 with 0.0% growth over the last 90 days, suggesting stagnant engagement or visibility on that platform and no recent surge in retail or public interest from this channel.
• LinkedIn followers total 38,863, which is relatively strong for a biotech of this profile and indicates a solid professional and industry-facing presence, but without growth data it is difficult to interpret as clearly bullish or bearish.

Atara Biotherapeutics shows a powerful bullish technical setup, with the stock trading far above its 200-day moving average and supported by a constructive RSI reading. Fundamentally, a very low PE multiple against positive EPS suggests either a deep value opportunity or significant skepticism about the durability and quality of earnings. With alternative data largely flat rather than clearly expansionary, the overall picture is balanced between strong momentum and elevated uncertainty, leading to a neutral overall stance.

• Technicals are clearly bullish, with strong upside momentum and a decisive break above long-term trend levels, but this also raises volatility and pullback risk.
• Fundamental valuation appears cheap on a PE basis, yet the market’s discount and muted alternative data signals imply investors remain cautious about long-term sustainability, justifying an overall neutral view.